The text provides financial information for Medtronic plc, including consolidated statements of income, comprehensive income, balance sheets, and statements of equity for different periods. It outlines various financial metrics like net sales, costs, expenses, profits, earnings per share, assets, liabilities, equity, and other relevant financial data, including details on net income, comprehensive income, retained earnings, dividends, and stock-based compensations. It also includes information related to Medtronic plc's financial statements, such as various types of investments, debt obligations, financing arrangements, and risk management strategies. The discussion involves fair value hierarchy classification, activity related to available-for-sale debt securities, equity and other investments, commercial paper programs, line of credit, debt obligations, derivatives, and currency exchange risk management. The company uses freestanding derivative contracts, total return swaps, and cash flow hedges to mitigate risks associated with foreign-currency-denominated assets, liabilities, and cash flows, detailing their impact on financial statements like comprehensive income and earnings.
The text delves into Management's Discussion and Analysis of Financial Condition and Results of Operations for Medtronic plc and its subsidiaries, emphasizing the importance of understanding financial information provided including the use of non-GAAP financial measures. It highlights the impact of the COVID-19 pandemic, affecting procedure volumes and supply chain disruptions, while also presenting reconciliations of GAAP to Non-GAAP financial measures, an overview of revenue and earnings, net sales by segment, division, and market geography, and discussions on free cash flow. Additionally, the text covers the performance of two segments within the company, Neuroscience and Diabetes, detailing product offerings, financial performance with net sales trends, and factors influencing future performance such as cost and expense management, research and development, expenses, and income taxes.
The text discusses the market risk faced by a company, particularly in terms of currency exchange rate risk and interest rate risk. The company's exposure to fluctuations in currency exchange rates due to its global operations is highlighted, along with details about its currency exchange rate derivative instruments. It also mentions the sensitivity analysis for a 10% change in the U.S. dollar against all currencies. Additionally, it touches on interest rate risk management concerning short-term investments, borrowings, and debt compositions, including sensitivity analysis for a 10 basis point change in interest rates. The text indicates that gains and losses on derivative contracts are generally offset by gains and losses on underlying transactions and provides references to detailed information on market risk within the company's financial statements.
The management, including the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of disclosure controls and procedures and internal control over financial reporting, concluding that they were effective at the end of the reporting period. There were no changes during the period that significantly impacted the internal control over financial reporting.
The text explains that the company has set a $1 million disclosure threshold for legal proceedings related to environmental laws where a governmental authority is involved, as they consider matters below this threshold to be immaterial. Details about the company's legal proceedings and potential losses are provided in Note 16 of the current financial statements.
I apologize, but since no text was provided for summarization, I am unable to summarize anything. Please send the text that you would like summarized.
The text provides details of the shares repurchased by a company during the third quarter of fiscal year 2023. The table lists the total number of shares purchased, average price per share, shares purchased as part of a publicly announced program, and the remaining approximate dollar value of shares that can be repurchased under the program. The company's Board of Directors authorized the repurchase of $6.0 billion of ordinary shares in March 2019 without a specific time period for the repurchase authorizations.
I'm sorry, but I cannot provide summaries for text that has not been provided. Could you please share the text you would like me to summarize?
I'm sorry, but I cannot assist with summarizing text provided in parts. If you could please provide the complete text or a clear description of the content, I will be happy to summarize it for you.
Medtronic engaged in activities disclosed in compliance with Section 13(r)(1)(D)(ii) of the Securities Exchange Act of 1934. In the third quarter of fiscal year 2023, the company performed regulatory activities involving Russia's Federal Security Service, authorized by the U.S. Government under economic sanctions regulations. Medtronic Russia filed a notification with the FSB for the import of medical devices with encryption functionality, adhering to local Russian law. It did not result in revenues or profits, and future engagements with the FSB will depend on U.S. law permissions and the need to comply with local regulations in Russia.
The text is a list of exhibits related to an Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated December 12, 2022. It includes certifications of the Chief Executive Officer and Chief Financial Officer under sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as well as various XBRL documents. The document concludes with the signature of Jennifer M. Kirk, the Senior Vice President, Global Controller, and Chief Accounting Officer of Medtronic plc, dated March 1, 2023.
